Home > Insider Trading > Filing (0001140361-24-013634)

Filing Details

Accession Number:: 0001140361-24-013634
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-03-15 21:00:30
Reporting Period:: 2024-03-13

Accepted Time:: 2024-03-15 21:00:30
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1368514	Adma Biologics Inc.	ADMA	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1250195	Steve Elms	888 Seventh Ave 12Th Floor New York NY 10106		No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2024-03-13	407,000	$6.21	3,208,671	No	4	S	Indirect	See footnote
Common Stock	Disposition	2024-03-14	448,276	$6.05	2,760,395	No	4	S	Indirect	See footnote
Common Stock	Disposition	2024-03-15	183,008	$6.01	2,577,387	No	4	S	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	76,441	Direct

Footnotes

These shares are owned by Aisling Capital II LP ("Aisling"), which is a fund that was established in 2007 with a 10 year life. Mr. Elms is Aisling's designee for nomination to the Board. As a Managing Member of Aisling Capital Partners, LLC ("Aisling Partners"), a control person of Aisling, and as a member of the investment committee of Aisling Capital Partners, LP ("Aisling GP"), Mr. Elms may be deemed to be the beneficial owner of shares of common stock owned of record by Aisling. Mr. Elms disclaims beneficial ownership of Aisling's investment in the Company and Aisling Partners' ownership of the Company's options, except to the extent of his pecuniary interest thereon.
The price shown in Column 4 is a weighted average sale price. The price range for the sales is $6.13 to $6.27. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
The price shown in Column 4 is a weighted average sale price. The price range for the sales is $6.02 to $6.20. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
The price shown in Column 4 is a weighted average sale price. The price range for the sales is $6.00 to $6.06. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Includes, as of the transaction date, (i) 24,040 restricted stock units ("RSUs") granted on February 26, 2024 and reported on this Form 4, that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date; and (ii) 52,401 shares of common stock owned by the reporting person.